IMX TACROLIMUS II
FDA premarket approval P970007/S002 · decided 2001-03-30
Approval details
- PMA number
- P970007
- Supplement
- S002
- Supplement type
- Special (Immediate Track)
- Supplement reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Trade name
- IMX TACROLIMUS II
- Generic name
- ENZYME IMMUNOASSAY, TRACROLIMUS
- Applicant
- Abbott Laboratories
- Date received
- 2001-02-27
- Decision date
- 2001-03-30
- Days to decision
- 31 days
- Decision code
- APPR
- Product code
- MLM
- Advisory committee
- Clinical Toxicology
- Expedited review
- No
- Location
- Abbott Park, IL
- Statement
- APPROVAL FOR A CHANGE TO THE CURRENT LABELING FOR THE DEVICE PER 21 CFR 814.39(D)(2). THE CURRENT PACKAGE INSERT STATES "HEMATOCRIT VALUES RANGING FROM 25 TO 45% RESULTED IN LESS THAN 12% ERROR IN DETECTING TACROLIMUS." THE PACKAGE INSERT WILL BE MODIFIED TO STATE "HEMATOCRIT INTERFERENCE WAS EVALUATED BY SPIKING KNOWN AMOUNTS OF TACROLIMUS INTO POOLED, WHOLD BLOOD SAMPLES DILUTED WITH SALINE. HEMATOCRIT VALUES RANGING FROM 25 TO 45% RESULTED IN LESS THAN 31% ERROR IN DETECTING TACROLIMUS.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.
510(k) clearances by this applicant
| Record | Firm | Date |
|---|---|---|
| Anti-HCV Next (K252424) | Abbott Laboratories | 2026-04-28 |
| ARCHITECT iGentamicin (K243500) | Abbott Laboratories | 2025-07-09 |
| Alinity i Rubella IgG (K243168) | Abbott Laboratories | 2025-06-20 |
| Alinity h-series System (K243283) | Abbott Laboratories | 2025-02-20 |
| Alinity i Toxo IgM (K233932) | Abbott Laboratories | 2024-08-30 |
| TBI (K232669) | Abbott Laboratories | 2023-09-29 |
| HAVAb IgG II (K222850) | Abbott Laboratories | 2023-08-10 |
| Alinity h-series System (K220031) | Abbott Laboratories | 2023-08-04 |